1021913-08-5

Upstream product

• 1021913-04-1 3-bromo-7-chloro-6-iodoquinolin-4-ol 
• 1021913-05-2 tert-butyl (2R)-2-{2-[(3-bromo-7-chloro-6-iodoquinolin-4-yl)oxy]ethyl}piperidine-1-carboxylate 
• 135050-44-1 3-chloro-4-iodoaniline 
• 1021913-03-0 7-chloro-6-iodoquinolin-4-ol 
• 1021913-07-4 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylic acid 
• 1021913-01-8 ethyl 7-chloro-4-hydroxy-6-iodoquinoline-3-carboxylate 
• 1021913-06-3 tert-butyl (2R)-2-(2-{[3-bromo-7-chloro-6-(1-methyl-1H-pyrazol-4-yl)quinolin-4-yl]oxy}ethyl)piperidine-1-carboxylate 
• 172975-69-8 3,5-dimethylphenyl boronic acid 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel 3,6-diaryl-4- aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2

Agonists of somatostatin receptor subtype 2 (sst2) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst2, and these were optimized to provide small molecules with sst2 binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.

SOMATOSTATIN AGONISTS

This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy,